A NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY STUDY.

PURPOSE To quantify changes of the retinal vascular bed area (RVBA) in mm2 on stereographically projected ultra-wide field (UWF) fluorescein angiography (FA) images by in eyes with proliferative diabetic retinopathy (PDR) following anti-vascular endothelial growth factor (VEGF) injection. METHODS Prospective, observational study. The early-phase UWF FA images (Optos 200Tx) of 40 eyes with PDR and significant non-perfusion obtained at baseline and after 6 months (NCT02863354) were stereographically projected by correcting peripheral distortion. The global retinal vasculature on UWF FA was extracted for calculating RVBA by summing the real size (mm2) of all the pixels automatically. RESULTS For the entire cohort, global RVBA for the entire retina decreased from 67.1 ± 15.5 mm2 to 43.6 ± 18.8 mm2 after anti-VEGF treatment at 6 months (P < 0.001). In the sub-group receiving monthly anti-VEGF injections, global RVBA decreased from 68.7 ± 16.2 mm2 to 33.9 ± 13.3 mm2 (P < 0.001). In the sub-group receiving anti-VEGF every 3 months, global RVBA decreased from 65.6 ± 15.1 mm2 to 50.8 ± 19.3 mm2 (P = 0.004). CONCLUSIONS RVBA appears to be a new biomarker to indicate efficiency of retinal vascular changes after anti-VEGF injection. Eyes with PDR and significant non-perfusion demonstrate reduced RVBA following anti-VEGF treatment.